Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Tsunoda

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
European Journal of Pharmacology|May 4, 2025
Combination therapy with cetirizine and anti-PD-1 antibody suppresses colitis-induced colon tumor formation in miceYuki Maruyama, Masahiro Hosonuma, Hitoshi Toyoda, et al.
BMC Cancer|April 21, 2022
Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancerJun Arai, Yumi Otoyama, Ken-Ichi Fujita, et al.
International Journal of Cancer|April 16, 2014
Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patientsYusuke Tomita, Akira Yuno, Hirotake Tsukamoto, et al.
Cancer Science|April 14, 2015
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC StudyHiroki Yamaue, Takuya Tsunoda, Masaji Tani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumorYusuke Tomita, Akira Yuno, Hirotake Tsukamoto, et al.
Cancer Genomics & Proteomics|December 27, 2024
Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint InhibitorsTomoyuki Ishiguro, Kazuyuki Takeda, Daisuke Takayanagi, et al.
Medicine|January 14, 2022
A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case reportKazuyuki Hamada, Kiyoshi Yoshimura, Kazuhiko Oshinomi, et al.
Biomedicines|December 24, 2021
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 AntibodiesRyotaro Ohkuma, Katsuaki Ieguchi, Makoto Watanabe, et al.
Journal of Translational Medicine|July 11, 2012
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigensKoji Kono, Hisae Iinuma, Yasunori Akutsu, et al.
International Journal of Cancer|September 5, 2008
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTLMichiko Harao, Shinya Hirata, Atsushi Irie, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
European Journal of Pharmacology|May 4, 2025
Combination therapy with cetirizine and anti-PD-1 antibody suppresses colitis-induced colon tumor formation in miceYuki Maruyama, Masahiro Hosonuma, Hitoshi Toyoda, et al.
BMC Cancer|April 21, 2022
Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancerJun Arai, Yumi Otoyama, Ken-Ichi Fujita, et al.
International Journal of Cancer|April 16, 2014
Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patientsYusuke Tomita, Akira Yuno, Hirotake Tsukamoto, et al.
Cancer Science|April 14, 2015
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC StudyHiroki Yamaue, Takuya Tsunoda, Masaji Tani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumorYusuke Tomita, Akira Yuno, Hirotake Tsukamoto, et al.
Cancer Genomics & Proteomics|December 27, 2024
Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint InhibitorsTomoyuki Ishiguro, Kazuyuki Takeda, Daisuke Takayanagi, et al.
Medicine|January 14, 2022
A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case reportKazuyuki Hamada, Kiyoshi Yoshimura, Kazuhiko Oshinomi, et al.
Biomedicines|December 24, 2021
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 AntibodiesRyotaro Ohkuma, Katsuaki Ieguchi, Makoto Watanabe, et al.
Journal of Translational Medicine|July 11, 2012
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigensKoji Kono, Hisae Iinuma, Yasunori Akutsu, et al.
International Journal of Cancer|September 5, 2008
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTLMichiko Harao, Shinya Hirata, Atsushi Irie, et al.
Pageof 13